MAINZ BIOMED N.V.

Analyst Reco. Mainz Biomed N.V.

Equities

MYNZ

NL0015000LC2

Market Closed - Nasdaq Other stock markets 16:30:00 2024-04-30 EDT			5-day change	1st Jan Change
0.8799 ^USD	+1.49%		+1.25%	-24.15%

04-25	Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel Mrna Biomarkers and Proprietary Ai Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic	CI
04-09	Mainz Biomed N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cantor Fitzgerald Downgrades Mainz Biomed to Neutral From Overweight	11-21	MT
HC Wainwright Adjusts Mainz Biomed's Price Target to $5 From $9, Keeps Buy Rating	11-20	MT
HC Wainwright Adjusts Mainz Biomed Price Target to $7 From $10, Maintains Buy Rating	23-08-18	MT
Cantor Fitzgerald Adjusts Price Target on Mainz Biomed to $12 From $15, Keeps Overweight Rating	23-05-18	MT
HC Wainwright Adjusts Price Target on Mainz Biomed to $10 From $25, Reiterates Buy Rating	23-04-27	MT
JonesTrading Initiates Mainz Biomed B.V at Buy With $11 Price Target	23-02-10	MT
Cantor Fitzgerald Starts Mainz Biomed at Overweight With $15 Price Target	22-10-25	MT
HC Wainwright Initiates Mainz Biomed at Buy With $25 Price Target	22-06-21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+201.5% on SUPER MICRO COMPUTER since our purchase on February 17, 2023

Replicate our performance

fermer